TIZANIDINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tizanidine Hydrochloride, and what generic alternatives are available?
Tizanidine Hydrochloride is a drug marketed by Alembic, Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Endo Operations, Jubilant Generics, Norvium Bioscience, Novast Labs, Rubicon, Somerset Theraps Llc, Zydus Pharms, Ani Pharms, Apotex, Aurobindo Pharma Usa, Cadila, Chartwell Rx, Dr Reddys Labs Inc, Epic Pharma Llc, Graviti Pharms, Oxford Pharms, Rising, Sun Pharm Inds Inc, and Unichem Labs Ltd. and is included in twenty-nine NDAs.
The generic ingredient in TIZANIDINE HYDROCHLORIDE is tizanidine hydrochloride. There are eleven drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the tizanidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tizanidine Hydrochloride
A generic version of TIZANIDINE HYDROCHLORIDE was approved as tizanidine hydrochloride by DR REDDYS LABS INC on July 3rd, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TIZANIDINE HYDROCHLORIDE?
- What are the global sales for TIZANIDINE HYDROCHLORIDE?
- What is Average Wholesale Price for TIZANIDINE HYDROCHLORIDE?
Summary for TIZANIDINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 24 |
| NDAs: | 29 |
| Finished Product Suppliers / Packagers: | 50 |
| Raw Ingredient (Bulk) Api Vendors: | 114 |
| Clinical Trials: | 30 |
| Patent Applications: | 1,269 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TIZANIDINE HYDROCHLORIDE |
| What excipients (inactive ingredients) are in TIZANIDINE HYDROCHLORIDE? | TIZANIDINE HYDROCHLORIDE excipients list |
| DailyMed Link: | TIZANIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for TIZANIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University | Early Phase 1 |
| Indiana University | Early Phase 1 |
| Kuwait University | Early Phase 1 |
Pharmacology for TIZANIDINE HYDROCHLORIDE
| Drug Class | Central alpha-2 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha2-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for TIZANIDINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for TIZANIDINE HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ZANAFLEX | Capsules | tizanidine hydrochloride | 2 mg, 4 mg and 6 mg | 021447 | 1 | 2007-08-10 |
US Patents and Regulatory Information for TIZANIDINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | TABLET;ORAL | 076371-001 | Apr 9, 2003 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Somerset Theraps Llc | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | CAPSULE;ORAL | 213365-002 | May 13, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Aurobindo Pharma Usa | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | TABLET;ORAL | 076282-002 | Dec 16, 2003 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
